Researchers Explore Possible Link Between GLP-1 Drugs and Erectile Dysfunction

A popular diabetes drug may come with an unexpected trade-off-sexual health concerns in men.

Medications known as GLP-1 receptor agonists, widely used to manage Type 2 diabetes and support weight loss, are now being linked to a modest increase in the risk of erectile dysfunction (ED), according to a recent 2026 study using a target trial emulation design published in the Journal eClinicalMedicine.

Researchers analyzed electronic health records of over 10,000 men in the United States who had Type 2 diabetes and were newly started on either GLP-1 drugs or DPP-4 inhibitors. Importantly, men with a prior history of ED were excluded to better assess new-onset cases.

The findings showed that men taking GLP-1 medications had a slightly higher incidence of ED—about 35 cases per 1,000 person-years—compared to 28 cases in those using DPP-4 inhibitors. This translates to roughly a 26% increased risk over a three-year period. While the difference is not dramatic, it is notable given that ED already affects nearly half of men with Type 2 diabetes during their lifetime.

However, the picture is far from definitive. When researchers applied stricter statistical adjustments, the association weakened and was no longer clearly significant. This suggests that other factors—such as obesity, cardiovascular health, or lifestyle differences—may partly explain the findings.

Clinically, the results highlight the need for a more holistic approach to diabetes care. While GLP-1 drugs are highly effective for blood sugar control and weight reduction, doctors may need to discuss potential sexual health implications with patients, especially those already at risk.

At the same time, experts caution against jumping to conclusions. The study does not prove that GLP-1 drugs directly cause erectile dysfunction. More rigorous randomized trials are needed to clarify whether this link is real or simply a reflection of underlying health differences.

REFERENCE: Tang H et al. GLP-1 receptor agonist and risk of erectile dysfunction in men with Type 2 diabetes: a target trial emulation. EClinicalMedicine. 2026;DOI:10.1016/j.eclinm.2026.103857.